The U.S. Food and Drug Administration has qualified the first artificial intelligence tool designed to help doctors assess a ...

NASH, has received FDA approval to revolutionize liver disease drug trials. This innovative technology assists pathologi ...

The FDA has qualified its first artificial intelligence tool to help drug developers evaluate fatty liver disease in their ...

The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...

Metabolic dysfunction-associated steatotic liver disease (MASLD), a spectrum of liver conditions ranging from simple steatosis to steatohepatitis (MASH), fibrosis, and cirrhosis, represents a global ...

Mirum Pharmaceuticals acquires Bluejay Therapeutics to expand its pipeline into liver diseases. Read more here.

MedPage Today brought together three hepatology experts for a virtual roundtable discussion on metabolic ...

MTVA READ THE FULL MTVA RESEARCH REPORT Business Update New Data from Phase 2a Trial of Vanoglipel (DA-1241) Presented at The ...

Experts convened in Cleveland, Ohio, on November 11, 2025, to discuss the evolution of cardio-renal-metabolic care from ...

In this health column, Texas Tech HSC's Dr. Hakan Akin shares some warning signs, tips and best practices about what he calls ...

Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

1. Lou A, Elnenaei M, Liu E, et al. Evaluation of a novel albumin platelet product (APP) fibrosis index and three ...